Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Sandra Van Lint

Publications & Research Data

Awards & Distinctions

46 Results

2024

A co-culture model to study modulators of tumor immune evasion through scalable arrayed CRISPR-interference screens

Ramiro MartinezChiara FinocchiaroLouis DelhayeFien GysensJasper AnckaertWim TrypsteenMaarten VerstevenEva LionSandra Van LintKarim Vermaelen et al.

A1 Journal Article in FRONTIERS IN IMMUNOLOGY

Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum

Joline IngelsLaurenz De CockDieter StevensRupert MayerFabien Henri TheryGuillem Sanchez SanchezDavid VermijlenKarin WeeningSaskia De SmetNele Lootens et al.

A1 Journal Article in CELL REPORTS MEDICINE

2023

A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state

Sandra Van LintAlexander Van ParysBram Van Den EeckhoutNiels VandammeStephane PlaisanceAnnick VerheeDominiek CatteeuwElke RoggeJennifer De GeestNele Vanderroost et al.

A1 Journal Article in MOLECULAR CANCER

2022

Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials

Joline IngelsLaurenz De CockRupert MayerPam DevrekerKarin WeeningKelly HeynsNele LootensSaskia De SmetMarieke BrusseelStijn De Munter et al.

A1 Journal Article in CYTOTHERAPY

2021

Dendritic cell-based immunotherapy in lung cancer

Dieter StevensJoline IngelsSandra Van LintBart VandekerckhoveKarim Vermaelen

A1 Journal Article in FRONTIERS IN IMMUNOLOGY

mRNA in cancer immunotherapy : beyond a source of antigen

Lien Van HoeckeRein VerbekeHeleen DewitteIne LentackerKarim VermaelenKarine BreckpotSandra Van Lint

A1 Journal Article in MOLECULAR CANCER

Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

Bram Van Den EeckhoutLeander HuygheSandra Van LintElianne BurgStéphane PlaisanceFrank PeelmanAnje CauwelsGilles UzéNiko KleySarah Gerlo et al.

A1 Journal Article in JOURNAL FOR IMMUNOTHERAPY OF CANCER

Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Anje CauwelsSandra Van LintElke RoggeAnnick VerheeBram Van Den EeckhoutShengru PangMarco PrinzNiko KleyGilles UzeJan Tavernier

A1 Journal Article in SCIENTIFIC REPORTS

2020

mRNA-based therapeutics to induce immunity against cancer and infectious diseases

Lien Van HoeckeXavier SaelensSandra Van LintKenny Roose

Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies

Leander HuygheAlexander Van ParysAnje CauwelsSandra Van LintStijn De MunterJennyfer BultinckLennart ZabeauJeroen HostensAn GoethalsNele Vanderroost et al.

A1 Journal Article in EMBO MOLECULAR MEDICINE

Selected IL-1 activity on CD8+ T cells allows for safe enhancement of cellular immune responses

Bram Van Den EeckhoutLien Van HoeckeElianne BurgSandra Van LintFrank PeelmanNiko KleyGilles UzéXavier SaelensJan TavernierSarah Gerlo

Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant

Bram Van Den EeckhoutLien Van HoeckeElianne BurgSandra Van LintFrank PeelmanNiko KleyGilles UzéXavier SaelensJan TavernierSarah Gerlo

A1 Journal Article in NPJ VACCINES

The opposing effect of type I IFN on the T cell response by non-modified mRNA-lipoplex vaccines Is determined by the route of administration

Lien Van HoeckeKenny RooseMarlies BallegeerZifu ZhongNiek SandersStefaan De KokerXavier SaelensSandra Van Lint

A1 Journal Article in MOLECULAR THERAPY-NUCLEIC ACIDS

2019

A novel leptin receptor antagonist uncouples leptin’s metabolic and immune functions

Lennart ZabeauJoris WaumanJulie DamSandra Van LintElianne BurgJennifer De GeestElke RoggeAnisia SilvaRalf JockersJan Tavernier

A1 Journal Article in CELLULAR AND MOLECULAR LIFE SCIENCES

Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice

Anje CauwelsSandra Van LintDominiek CatteeuwShengru PangFranciane PaulElke RoggeAnnick VerheeMarco PrinzNiko KleyGilles Uzé et al.

A1 Journal Article in JOURNAL OF AUTOIMMUNITY

Towards the use of interleukin-1β as vaccine adjuvant

Bram Van Den EeckhoutLien Van HoeckeElianne BurgSandra Van LintFrank PeelmanXavier SaelensJan TavernierSarah Gerlo

2018

Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments

Anje CauwelsSandra Van LintFranciane PaulGenevieve GarcinStefaan De KokerAlexander Van ParysThomas WüestSarah GerloJosé Van Der HeydenYan Bordat et al.

A1 Journal Article in CANCER RESEARCH

IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination

Bram Van Den EeckhoutElianne BurgAnje CauwelsFrank PeelmanSandra Van LintJan TavernierSarah Gerlo

Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses

Lutz NuhnStefaan De KokerSandra Van LintZifu ZhongJoão Portela CataniFrancis CombesKim DeswarteYupeng LiBart LambrechtStefan Lienenklaus et al.

A1 Journal Article in ADVANCED MATERIALS

Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes

Lien Van HoeckeSandra Van LintKenny RooseAlexander Van ParysPeter VandenabeeleJohan GrootenJan TavernierStefaan De KokerXavier Saelens

A1 Journal Article in NATURE COMMUNICATIONS

2017

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

Anje CauwelsSandra Van LintGeneviève GarcinJennyfer BultinckFranciane PaulSarah GerloJosé Van Der HeydenYann BordatDominiek CatteeuwLode De Cauwer et al.

A1 Journal Article in ONCOIMMUNOLOGY

IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination

Bram Van Den EeckhoutElianne BurgAnje CauwelsFrank PeelmanSandra Van LintJan TavernierSarah Gerlo

2016

Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells

Sandra Van LintDries RenmansKatrijn BroosLode GoethalsSarah MaenhoutDaphné BenteynCleo GoyvaertsStephanie DufourKevin Van Der JeughtLukasz Bialkowski et al.

A1 Journal Article in CANCER IMMUNOLOGY RESEARCH

Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses

Ans De BeuckelaerCharlotte PollardSandra Van LintKenny RooseLien Van HoeckeTom NaessensVimal Kumar UdhayakumarMuriel SmetNiek SandersStefan Lienenklaus et al.

A1 Journal Article in MOLECULAR THERAPY

2015

Intratumoral delivery of mRNA : overcoming obstacles for effective immunotherapy

Kevin Van Der JeughtSandra Van LintKris ThielemansKarine Breckpot

A1 Journal Article in ONCOIMMUNOLOGY

Microbubbles as magic bullets in cancer immunotherapy

Heleen DewitteSandra Van LintKatrien VanderperrenHendrik HaersEmmelie StockStefaan De SmedtKarine BreckpotIne Lentacker

Targeting the tumor microenvironment to enhance antitumor immune responses

Kevin Van Der JeughtLukasz BialkowskiLidia DaszkiewiczKatrijn BroosCleo GoyvaertsDries RenmansSandra Van LintCarlo HeirmanKris ThielemansKarine Breckpot

A1 Journal Article in ONCOTARGET

The ReNAissanCe of mRNA-based cancer therapy

Sandra Van LintDries RenmansKatrijn BroosHeleen DewitteIne LentackerCarlo HeirmanKarine BreckpotKris Thielemans

A1 Journal Article in EXPERT REVIEW OF VACCINES

2014

Development of a local treatment modality for the systemic cure of cancer using mRNA as a medicinal product

Sandra Van LintKris ThielemansKarine Breckpot

Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts

Sarah K MaenhoutSandra Van LintPerpetua U EmegiKris ThielemansJoeri L Aerts

A1 Journal Article in INTERNATIONAL JOURNAL OF CANCER

Immunogenicity of targeted lentivectors

Cleo GoyvaertsKurt De GroeveSandra Van LintCarlo HeirmanJo A VanginderachterPatrick De BaetselierGeert RaesKris ThielemansKarine Breckpot

A1 Journal Article in ONCOTARGET

Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula

Sandra Van LintSofie WilgenhofCarlo HeirmanJurgen CorthalsKarine BreckpotAude BonehillBart NeynsKris Thielemans

A1 Journal Article in CANCER IMMUNOLOGY IMMUNOTHERAPY

The bubble breakthrough in cancer immunotherapy

Heleen DewitteSandra Van LintKatrien VanderperrenStefaan De SmedtKarine BreckpotIne Lentacker

The bubble breakthrough in cancer immunotherapy : Mma-sonoporation in dendritic cell-based cancer vaccination

Heleen DewitteSandra Van LintKatrien VanderperrenKris ThielemansStefaan De SmedtKarine BreckpotIne Lentacker

The bubble breakthrough in cancer immunotherapy : Mma-sonoporation in dendritic cell-based cancer vaccination

Heleen DewitteSandra Van LintKatrien VanderperrenKris ThielemansStefaan De SmedtKarine BreckpotIne Lentacker

The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy

Heleen DewitteSandra Van LintCarlo HeirmanKris ThielemansStefaan De SmedtKarine BreckpotIne Lentacker

A1 Journal Article in JOURNAL OF CONTROLLED RELEASE

2013

Design of an optimized Wilms' tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo

Daphné BenteynSébastien AnguilleSandra Van LintCarlo HeirmanAn MT Van NuffelJurgen CorthalsSebastian OchsenreitherWim WaelputKatrien Van BenedenKarine Breckpot et al.

A1 Journal Article in MOLECULAR THERAPY-NUCLEIC ACIDS

mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic

Sandra Van LintCarlo HeirmanKris ThielemansKarine Breckpot

Editorial material

Priming of cytotoxic T lymphocyte responses by dendritic cells: induction of potent anti-tumor immune responses

Sandra Van LintAn MT van NuffelSofie WilgenhofDaphné BenteynJoeri PenDavid EscorsAude BonehillBart NeynsKris ThielemansKarine Breckpot

Bookchapter in Horizons in Cancer Research, vol. 51

2012

Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells

Cleo GoyvaertsKurt De GroeveJozef DingemansSandra Van LintLander RobaysCarlo HeirmanJ ReiserKris ThielemansPatrick De BaetselierGeert Raes et al.

A1 Journal Article in GENE THERAPY

Preclinical evaluation of TriMix and antigen mRNA-based anti-tumor therapy

Sandra Van LintCleo GoyvaertsSarah MaenhoutLode GoethalsAurélie DisyDaphné BenteynJoeri PenAude BonehillCarlo HeirmanKarine Breckpot et al.

A1 Journal Article in CANCER RESEARCH

Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy

Perpetua U EmeagiSandra Van LintCleo GoyvaertsSarah MaenhoutAnje CauwelsLain A McNeishTomas BosCarlo HeirmanKris ThielennansJoeri L Aerts et al.

A1 Journal Article in CANCER RESEARCH

2011

mRNA: delivering an anti-tumor message?

Sandra Van LintKris ThielemansKarine Breckpot

A1 Journal Article in IMMUNOTHERAPY

2010

HIV-1 Lentiviral vector immunogenicity is mediated by Toll-Like Receptor 3 (TLR3) and TLR7

Karine BreckpotDavid EscorsFrederic ArceLucienne LopezKatarzyna KarwaczSandra Van LintMarleen KeyaertsMary Collins

A1 Journal Article in JOURNAL OF VIROLOGY

Large double copy vectors are functional but show a size-dependent decline in transduction efficiency

Tomas J BosSandra Van LintCarlo HeirmanKarin Vanderkerken

A1 Journal Article in JOURNAL OF BIOTECHNOLOGY

2009

A 'super IRES' improves bicistronic expression in lentiviral 2A vectors

Tomas BosLuc BaeyensSandra Van LintCarlo HeirmanKarine Vanderkerken